Navigation Links
Minimally Invasive Treatment Offers Hope for Liver Cancer Patients
Date:3/13/2008

In 2007, over 85% of liver cancer treatments performed in interventional

radiology suites used transcatheter chemoembolization, according to

Millennium Research Group

WALTHAM, Mass., March 13 /PRNewswire/ -- Data from Millennium Research Group's (MRG's) US Interventional Radiology (IR) Marketrack(TM) indicates that in 2007, over 85% of liver cancer treatments performed in IR suites used transcatheter chemoembolization, a procedure that delivers chemotherapy agents directly to a tumor through minimally invasive means.

Microsphere particles, including Boston Scientific's Contour SE, Biosphere Medical's Embosphere, and others, were used in 40% of these treatments. Overall, chemoembolization particles generated nearly 20% of total microsphere revenue. As such, chemoembolization procedures are a key segment in the overall embolic particle market, which, in addition to standard microspheres, includes drug-infused microspheres, selective internal radiation therapy (SIRT) spheres, and polyvinyl alcohol (PVA) particles. MRG's US IR Marketrack(TM) service monitors the adoption of embolic particles for liver cancer, uterine fibroids, aneurysms, hemorrhages, and vascular anomalies.

"In chemoembolization, chemotherapy agents are mixed with embolic particles and are delivered through a catheter directly to the tumor, thereby localizing the chemo treatment" says Phil Scrutton, Analyst at MRG. "The particles also embolize the surrounding arteries, blocking blood flow to the cancerous tissue. This slows diffusion of the chemotherapy agents away from the tumor, which increases its effectiveness in targeting the liver tumor, while the embolization also deprives the tumor of oxygen and nutrients."

Liver cancer has historically had a poor prognosis, but the use of embolic particles in conjunction with drugs in chemoembolization, while not a cure, is leading to longer life expectancies for cancer sufferers. These positive clinical outcomes, the availability of improved embolization technologies, and an increasing rate of patient referrals for this treatment are all contributing to embolic particle market growth.

Millennium Research Group will be attending the Society of Interventional Radiology annual meeting in Washington, DC from March 16-19. Come to booth #304 to discover how we can help you meet your needs.

About Interventional Radiology Marketrack(TM)

IR Marketrack(TM) gathers quarterly data from interventional radiology labs throughout the US, including data on PV embolizations, varicose vein treatments, and vascular access procedures. Marketrack(TM) subscribers receive thousands of data points, including usage (units, average selling price, and revenue), procedure, competitor, and device brand information.

About Millennium Research Group

Millennium Research Group (http://www.MRG.net), a Decision Resources, Inc. company (http://www.DecisionResources.com), is the global authority on medical technology market intelligence and a leading provider of strategic information to the health care sector. Focused solely on the medical device, pharmaceutical, and biotechnology industries, the company provides its clients with the benefits of its specialized industry expertise through published reports and customized consulting services.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Amy Krohn

Millennium Research Group

416-364-7776 x101

akrohn@mrg.net


'/>"/>
SOURCE Millennium Research Group
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Microfabrica Introduces Set of Miniature Building Blocks for Minimally-Invasive Medical Devices
2. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
3. Cheetah Medicals NICOM Non-Invasive Cardiac Output Monitor Featured in a Presentation at the Heart Failure Society of America (HFSA) Annual Meeting
4. InSightec Resumes Clinical Trials for Non-Invasive Treatment of Brain Tumors
5. Masimo Launches Patient SafetyNet and Showcases the Rainbow SET Upgradable Noninvasive Monitoring Platform at 2007 ASA Annual Meeting
6. Masimo Announces Continuous Noninvasive Total Hemoglobin
7. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
8. Johns Hopkins to add Elekta Synergy S(R) to Cancer Treatment Lineup
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
11. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... Iowa (PRWEB) , ... October 12, 2017 , ... ... based in Vilnius, Lithuania, announced today that they have entered into a multiyear ... is to provide CRISPR researchers with additional tools for gene editing across all ...
(Date:10/12/2017)... ... October 12, 2017 , ... AMRI, a global contract ... to improve patient outcomes and quality of life, will now be offering its ... attributed to new regulatory requirements for all new drug products, including the finalization ...
(Date:10/11/2017)... YORBA LINDA, CA (PRWEB) , ... October 11, ... ... adapted to upregulate any gene in its endogenous context, enabling overexpression experiments and ... activation (CRISPRa) system with small RNA guides is transformative for performing systematic gain-of-function ...
(Date:10/11/2017)... ... October 11, 2017 , ... Proscia Inc ... hosting a Webinar titled, “Pathology is going digital. Is your lab ready?” with ... adoption best practices and how Proscia improves lab economics and realizes an increase ...
Breaking Biology Technology:
(Date:4/5/2017)... Allen Institute for Cell Science today announces the launch ... dynamic digital window into the human cell. The website ... deep learning to create predictive models of cell organization, ... suite of powerful tools. The Allen Cell Explorer will ... resources created and shared by the Allen Institute for ...
(Date:4/4/2017)...   EyeLock LLC , a leader of iris-based ... Patent and Trademark Office (USPTO) has issued U.S. Patent ... an iris image with a face image acquired in ... 45 th issued patent. "The ... the multi-modal biometric capabilities that have recently come to ...
(Date:3/30/2017)... The research team of The Hong Kong Polytechnic University ... adopting ground breaking 3D fingerprint minutiae recovery and matching technology, pushing ... for use in identification, crime investigation, immigration control, security of access ... ... A research team led by Dr Ajay ...
Breaking Biology News(10 mins):